Healthcare Industry Insights: May 2019

Thursday 30 May 2019

Herbal Supplements Market Size is Predicted to Register CAGR 6.2% till 2025

The global Herbal Supplements Market size is expected to reach USD 8.5 billion by 2025, according to a new report by Grand View Research, Inc. It is projected to expand at a CAGR of 6.2% over the forecast period (from 2018 to 2025). Growing geriatric population and awareness regarding preventive healthcare are expected to be the key factors driving the market. Rising healthcare expenditure is also likely to augment the market growth. Easy availability of herbal supplements owing to various strategies, such as direct selling and bundled offerings, adopted by companies will also support market growth.

Increasing awareness regarding the benefits associated with the consumption of herbal supplements is also likely to have a positive impact on the product demand. Manufacturers are focusing on product placement strategies to increase their sale across all consumer groups. For instance, the advertisements targeting children segment are focused on endorsing the use of supplements for nutritional values for healthy growth. According to the article cited by NCBI in 2013, nearly 80% of the global population relies on herbal supplements as part of primary healthcare. Thus, increasing acceptance of natural therapies and products is also propelling the market growth.

To request a sample copy or view summary of this report, click the link below:
https://www.grandviewresearch.com/industry-analysis/herbal-supplements-market

Further key findings from the study suggest:

Echinacea supplements segment accounted for the largest revenue share in 2017 owing to high adoption of these supplements for infection prevention
Turmeric supplements segment is expected to emerge with the fastest CAGR 8.1% over the forecast period owing to the rising clinical studies demonstrating the therapeutic benefits of these supplements
Capsule segment accounted for the largest revenue share in 2017 owing to the large number of products available in capsule form
Adult segment emerged as the largest consumer group in the past while pregnant women segment is expected to emerge with the fastest CAGR 7.0% over the forecast period
Asia Pacific was the largest regional market; however, Europe is anticipated to witness the fastest CAGR of 8.2% over the forecast period
Jarrow Formulas, Inc.; Solgar, Inc.; Nature’s Bounty; Ancient GreenFields Pvt. Ltd.; Gaia Herbs; and Now Foods are some of the key companies in the herbal supplements market

About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
Blog: https://healthcareforecastreport.blogspot.com/

Gastroesophageal Reflux Disease (GERD) Therapeutics Market Overview and Outlook, 2025

The global Gastroesophageal Reflux Disease (GERD) Therapeutics Market is expected to reach USD 4.34 billion by 2025, according to a new study by Grand View Research, Inc. The incidence of acid reflux disorder, also known as heartburn, is rapidly increasing worldwide. Various studies state that almost every person experiences acid reflux once in a lifetime.

The overall market has been experiencing a downturn in terms of revenue in the past several years as the leading drugs for GERD treatment have lost their patent protection, with their market shares now largely consumed by over-the-counter (OTC) and generic medications. Although loss of exclusivity of high-grossing drugs have caused a market fall-off, the demand for acid reducing drugs due to the high prevalence and incidence levels of GERD will prove beneficial to the industry from a commercial standpoint.

GERD is one of the commonly observed recurrent gastrointestinal disorders worldwide. The prevalence of acid reflux and related symptoms has increased across the globe by nearly 50% over the last decade. This disorder not only has major effects on the health and quality of patient lives, but also extends to the healthcare system and economy.

In addition, the occurrence of acid reflux disease increases with age, rendering elderly people more prone to developing a severe form of heartburn. The geriatric subset hence forms a prominent target population for GERD therapeutics.

To request a sample copy or view summary of this report, click the link below:
http://www.grandviewresearch.com/industry-analysis/gastroesophageal-reflux-disease-gerd-therapeutics-market

Further key findings from the study suggest:

Antacids have been identified as the largest drug type segment in terms of revenue share due to their cost-effectiveness and greater consumer accessibility
The rising trend of self-medication in case of heartburn is particularly responsible for the growth in sales of OTC antacids
Proton pump inhibitors accounted for the second largest segment as they are the most commonly prescribed medication for the treatment of acid reflux
Market share of proton pump inhibitors is expected to decline over the forecast period with the loss of patent protection of several leading drugs, such as Nexium and Prilosec, in this segment
North America accounted for the largest regional market in 2016 owing to the presence of a large patient population suffering from heartburn and the availability of OTC generics
On the other hand, Asia Pacific is expected to grow at a fairly high growth rate as compared to other regional markets due to increased adoption of OTC and generic antacids along with rising prevalence of heartburn

Grand View Research has segmented the GERD therapeutics market on the basis of drug type and region:

GERD Therapeutics Drug Type Outlook (Revenue, USD Million, 2014 - 2025)

Antacids
H2 Receptor Blockers
Proton Pump Inhibitors (PPIs)
Pro-kinetic agents

GERD Therapeutics Regional Outlook (Revenue, USD Million, 2014 - 2025)

North America

U.S.
Canada

Europe

UK
Germany

Asia Pacific

Japan
China
India

Latin America

Brazil

Middle East and Africa (MEA)

South Africa

Monday 27 May 2019

Research Insights on Vaccine Adjuvants Market, 2018-2025

The global Vaccine Adjuvants Market is expected to reach USD 758.8 million by 2025, according to a new report by Grand View Research, Inc. The significance of adjuvant research in the development of vaccines has increased gradually due to inadequate immunogenicity of innovative vaccine antigens. In addition, the growing focus on long-lasting immunization effect against existing and emerging diseases is expected to boost the demand for vaccine adjuvants.

Furthermore, rising prevalence of cervical cancer is anticipated to boost the market. According to NCBI, around 15,000 females die every year due to cervical cancer. There are certain companies developing vaccine adjuvants for this type of cancer in order to enhance the efficacy, such as AS04 adjuvant-adsorbed (human papillomavirus vaccine) by GSK, which boosts the immune response for a longer duration.

Browse Details of Report @
http://www.grandviewresearch.com/industry-analysis/vaccine-adjuvants-market

Further Key Findings From The Report Suggest:

Particulate product type dominated the market in 2016 due to greater efficiency of vaccines, presence of wide range of products, easier availability, and improved safetyPathogen is anticipated to be the fastest growing segment with a CAGR of 11.9% due to the availability of naturally occurring pathogens used as adjuvants
Among the route of administration, intramuscular held the largest market share in 2016 due to the high immune specificity of vaccines
Infectious disease segment dominated the market in 2016 by application, due to the increasing prevalence of infectious diseases such as hepatitis A, B, C, influenza, meningitis, and others
Cancer is expected to be the fastest growing application segment because of the rising prevalence of cancer and growing R&D activities to treat various types of cancer
Geographically, North America held the largest market share due to increase in favorable government initiatives and presence of well-established healthcare services.
Asia Pacific is estimated to be the fastest growing region over the forecast period with a significant CAGR from 2017 to 2025 due to the presence of huge target population and rise in disposable income
Some of the key players of the market include GlaxoSmithKline plc.; Novavax, Inc.; Adjuvance Technologies, Inc.; SPI Pharma; Agenus, Inc.; CSL Limited; InvivoGen; and Brenntag BiosectorMost of the key participants are focusing on strategies such as mergers & acquisitions, collaborations, and expansion of their product portfolios

In December 2015, SPI Pharma agreed to collaborate with Asahi Kasei Corporation. Both the companies agreed to sell each other’s products in their respective markets: Japan and North America.

Grand View Research has segmented the global vaccine adjuvants market on the basis of type, application, route of administration, and region:

Type Outlook (Revenue, USD Million; 2014 - 2025)

Pathogen
Adjuvant Emulsion
Particulate
Combination
Others

Administration Outlook (Revenue, USD Million; 2014 - 2025)

Oral
Intradermal
Intranasal
Intramuscular
Others

Application Outlook (Revenue, USD Million; 2014 - 2025)

Infectious Disease
Cancer
Others

Regional Outlook (Revenue, USD Million; 2014 - 2025)

North America

U.S.
Canada

Europe

Germany
UK

Asia Pacific

China
Japan

Latin America

Brazil

South Africa

About Us:

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
Blog: https://healthcareforecastreport.blogspot.com/

Wednesday 22 May 2019

Asthma Therapeutics Market - Industry Size and Overview

Global Asthma Therapeutics Market is expected to reach USD 25.6 billion by 2024, according to a new study by Grand View Research, Inc.

The increasing prevalence of asthma coupled with the adoption of biologics as a long-term treatment option to treat the severe form of asthma is expected to offer this market with lucrative growth opportunities. According to the statistics published by the World Allergy Journal, in May 2014, patients suffering from asthma registered around 300 million and the number is expected to soar due to a large number of individuals inclining towards unhealthy dietary habits and sedentary lifestyles.

In addition, patent expiration of branded drugs, such as Singulair, Advair and other major drugs during the forecast period has led to a stiff generic competition, which will negatively impact the asthma therapeutics market growth in the coming years. On the contrary, the introduction of biologics is accruing towards the increasing market share of the asthma therapeutics segment, and is anticipated to continue during the forecast period.

The enhanced demand for personalized medicine approach as opposed to the conventional medication prescription pattern for treatment of severe asthma is anticipated to aid the emergence of asthma therapeutics market in the future. In addition, development of technologically advanced products, such as pressurized metered dose inhalers and smart inhalers, equipped with sensor technology and inbuilt wireless communication system is further expected to propel the asthma therapeutics market growth in the next seven years.

Browse Details of Report @
http://www.grandviewresearch.com/industry-analysis/asthma-therapeutics-market

Further key findings from the study suggest:

The anti-inflammatory drug class is expected to exhibit rapid growth at a lucrative CAGR of 3.4% over the forecast period owing to the introduction of affordable and innovative biologics targeting the severe asthma condition. In addition, the awareness gained pertaining to the benefits rendered by the biologics and monoclonal antibodies is anticipated to exhibit an upward shift in the market expansion in the coming years.
The dry powder inhalers (DPIs) are expected to be the fastest growing segment due to the increasing adoption of these devices because of their high clinical efficiency than other inhalers. They are able to deliver both, small and large-sized drug components and dispense specialty engineered molecules. These related merits have spiked the adoption rates thereby contributing towards the risen market penetration.
Rising number of individuals opting for alternative treatment options, such as inhaled fixed-dose combination drugs for asthma medication is anticipated to serve this market with future growth opportunities. The inhalers market is expected to grow at a CAGR of above 2.0% over the forecast period.
Some of the key players operating in the asthma therapeutics market include AstraZeneca Plc, Philips Healthcare, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline Plc, Sanofi-Aventis SA, CareFusion Corporation, Sunovion Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, Roche Diagnostics, and Merck& Co., Inc.
Market leaders are focusing on the introduction of technologically advanced devices and novel, improved biologics to gain a competitive advantage. The asthma therapeutics segment has a very strong pipeline as there are almost 100 novel molecules that are in the development phase and manufacturers are focusing on the development of personalized medication. The aforementioned factors collectively strengthen the industry growth in the near future.
For instance, drug molecules, such as Cinquil by Teva Pharmaceutical Industries Ltd., Lebrikizumab by Roche (Phase III), Mastinib by AB Science (Phase II/III), and Bosatria by GlaxoSmithKline Plc (Phase III), are in the development stage undergoing clinical research trials. Their commercial availability during the forecast period is expected to provide a boost to this vertical.

Monday 20 May 2019

North America PoC Diagnostics Market Size, Share, Industry Outlook and Overview, 2024

The North America Point of Care Diagnostics Market is anticipated to reach USD 8.95 billion by 2024, according to a new report by Grand View Research, Inc. Incorporation of advanced information technology solutions coupled with the launch of innovative POC products with automation and ease of use is projected to influence market progression during the forecast period.

Moreover, the rising adoption rate of the POC devices in order to obtain quick results for immediate decision making for patient management is expected to provide the market with lucrative growth avenues. Additionally, the regulatory initiatives introduced for patient care management and rising prevalence of various diseases is attributive to boost demand for these products in the coming years.
The presence of a favorable funding environment in the region is attributive to drive R&D in academic organizations and universities thereby resulting to industrial progress through to 2024.

Browse Details of Report @ http://www.grandviewresearch.com/industry-analysis/north-america-point-of-care-poc-diagnostics-market

Further key findings from the report suggest:

Glucose testing accounted for the largest share of over 41% of the market in 2015 with respect to revenue generation. Factors attributive for the estimated large share includes presence of comprehensive product portfolio provided by the local as well as international market participants. Moreover, rise in the prevalence of diabetes in chronic patients and need for monitoring glucose levels is also supportive for revenue generation of this segment.

Infectious diseases point-of-care tests are expected to witness the fastest growth in the coming years owing to the R&D carried out in this segment for an introduction of novel tests. Infectious disease testing segments include kits for various diseases such as HIV, HBV, respiratory syncytial virus (RSV), pneumonia or streptococcus associated infections, HPV, influenza/flu, HCV, MRSA, Clostridium difficile, TB &drug-resistant TB, and HSV.

Cardiac markers are also anticipated to register substantial growth as a result of an increase in incidence rate of cholesterol associated disorders and rise in the number of cases of congestive heart failure.

Clinics dominated the POC diagnostic market in 2015 due to higher usage of these tests in clinics. However, home settings for POC diagnostics are anticipated to witness the fastest growth owing to rising usage of home health care settings for disease monitoring in the geriatric population.

Assisted living healthcare facilities are also anticipated to witness considerable growth during the forecast period due to the property of rapid diagnostic products to enable simple usage at primary care level and in remote settings even with no laboratory infrastructure

Prominent players of this industry include Qiagen N.V., Spectral Diagnostics, Abbott Laboratories, Siemens Healthcare, Instrumentation Laboratory, Danaher Corporation, BioMerieux, Johnson & Johnson, Abaxis Inc., Roche Diagnostics, Alere Inc., Nova Biomedical, Nipro Diagnostics, and Trinity Biotech.

Strategies adopted by the market players include mergers and acquisitions with the smaller entities operating in market for enhancement of the product portfolio. The participants are involved introduction of new solutions, and collaborations with heath care institutions in order to maintain their global presence.

Grand View Research has segmented North America point of care diagnostics market on the basis of product, end-use, and region:
North America Point of Care Diagnostics Outlook, by Product (Revenue, USD Million, 2013 - 2024)

Glucose Testing
Hb1Ac Testing
Coagulation
Fertility
Cardiac markers
Infectious diseases
- HIV POC
- Clostridium difficile POC
- HBV POC
- Pneumonia or Streptococcus associated infections
- Respiratory syncytial virus (RSV) POC
- HPV POC
- Influenza/Flu POC
- HCV POC
- MRSA POC
- TB and drug-resistant TB POC
- HSV POC
- Other Infectious Diseases
Primary care systems
Hematology
Decentralized Clinical Chemistry
Feces
Blood Gas/Electrolytes
Ambulatory Chemistry
Urinalysis
Drug Abuse Testing

North America Point of Care Diagnostics Outlook, by End-use (Revenue, USD Million, 2013 - 2024)

Clinics
Hospitals
Assisted Living Healthcare Facilities
Laboratory
Others

North America Point of Care Diagnostics Regional Outlook (Revenue, USD Million, 2013 - 2024)

North America
- U.S.
- Canada

About Us:Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
Blog: https://healthcareforecastreport.blogspot.com/

Chemoinformatics Market in North America to Gain Largest Share

The global Chemoinformatics Market is expected to reach over USD 21.18 billion by 2024 according to a new report published by Grand View Research, Inc. Some major determinants influencing the market growth include the constantly improving modern drug development processes, increasing use of in-silico techniques in research, and the advantages associated with employing the chemoinformatics approach, such as the reduction in the overall R&D expenditure during the drug development process.

The ever increasing growth of the drug development market will boost the demand for chemoinformatics owing to its numerous applications in drug designing at various stages. Right from target identification to its development as a potential drug candidate, chemoinformatics tools play a crucial part.

The significant contributions of the varying in silico tools in the generation of hits through the High Throughput Screening(HTS) process, target compound selection, virtual structure generation, Pharmacokinetic property and toxicity prediction of chemical compounds, and the quantitative-structure relationship determination have been a major driving force for the growth of the chemoinformatics market.

The heavy costs incurred along with the long time span invested in the drug discovery process has made the integration of the chemoinformatics techniques essential in the research activities. It aids the scientists and chemical researchers in making better decisions pertaining to drug discovery and other related research studies. Furthermore, the increasing demand for efficient and effective medicines, rising investments in R&D, growing geriatric population, and the burgeoning number of individuals with lifestyle related diseases are expected to positively reinforce the market growth. The key applications of the chemoinformatics tools and softwares in drug designing and discovery has been its largest application and is expected to grow further with further advances in the drug discovery process.

Chemoinformatics has made marked contributions to the areas of chemical drug development and research. The growth of this field is driven by the continually generated raw data in screening operations and research studies. Chemoinformatics in silico tools aid in effective data management, which facilitate data retrieval and analysis thus providing large databases of accessible information to scientists involved in both, the drug development process and other research related studies.

The development of three dimensional chemical structure databases has been a significant achievement in the field of chemoinformatics as it has significantly aided the research process. Applications of chemoinformatics platforms in computer-assisted synthesis designing, computer-assisted structure elucidation, and chemometrics have further contributed to the market growth.

The advancements in computational technology have been a high impact rendering driver for the market growth. In this direction, the development of super computers and silicon graphics computer for calculations, 3D structure generation, molecular graphics, and complex data display have been pivotal in propelling the growth of the chemoinformatics market. With the advent of advanced WEB technologies and their incorporation in the in-silico computational techniques have totally revolutionized this field.

The increasing needs for advanced and efficient technologies to yield better results has made the chemoinformatics area an indispensable part of the pharmaceutical industry. The surging need for therapeutically-effective medicines coupled with the increasing investments in the R&D area and the advancements in computer technologies provide lucrative opportunities to the market for it to grow and flourish in the near future.

Browse Details of Report @
http://www.grandviewresearch.com/industry-analysis/chemoinformatics-market

Further key findings from the study suggest:

In 2015, North America dominated the chemoinformatics market with a revenue share of over 36% on account of the following factors: the high investments pertaining to the R&D initiatives, technological advancements, the presence of major players in the drug manufacturing industry, and the increasing prevalence of lifestyle-related diseases. With respect to the global R&D spending, North America holds the largest share. Also, it holds a major share in the ADME-toxicology market that further spurs the growth of the chemoinformatics market.

Asia Pacific is identified as one of the fastest growing regional markets, growing at a lucrative CAGR of 18.3% during the forecast period. The growth of this market can be attributed to the growing research activities being conducted in economies, such as India, China, and Singapore. The key advantages associated with undertaking research activities in these countries include the low manufacturing and labor costs and the less stringent regulations, which attract many multinational players to the Asia Pacific region. Additionally, the government initiatives and funds that are deployed to improve the R&D infrastructure will further drive the market growth.

Key players operating in the market include Agilent Technologies, Inc., BIOVIA (Accelrys), Bio-Rad Laboratories, Inc., CambridgeSoft Corp., ChemAxon, Inc., ACD/Labs, Inc., Schrödinger, LLC, and Chemical Computing Group, Inc. Additionally, the rising demand for in-silico techniques in the research sector is expected to provide new market entrants with profitable opportunities thereby driving the market growth.

Grand View Research has segmented the chemoinformatics market by applications:

Global Chemoinformatics Market, by Application (USD Billion, 2013 - 2024)

Chemical Analysis
Drug Discovery
Drug Validation
Others

Chemoinformatics Market Regional Outlook, by Revenue (USD Billion, 2013 - 2024)

North America

U.S.
Canada

Europe

Germany
UK

Asia Pacific

Japan
China
India

Latin America

Brazil
Mexico

South Africa

Friday 17 May 2019

Global Kidney Cancer Drugs Market is Anticipated to Exhibit 5.4% CAGR till 2022

The global Kidney Cancer Drugs Market size is expected to be valued at USD 6.3 billion by 2022, as per a new report by Grand View Research, Inc., registering a CAGR of 5.4% during the forecast period. Market growth is largely driven by factors such as availability of novel drugs and presence of a strong pipeline. Growth can also be attributed to rise in incidence of renal cancer due to growing geriatric population and changes in lifestyle such as increased smoking and intake of alcohol.

In 2012, kidney cancer was the 13^th most prevalent cancer worldwide, accounting for approximately 2.0% of all adult malignancies. Kidney and renal pelvis cancer make up for 3.8% of all new cancer cases in U.S. Renal cell carcinoma account for over 90.0% of kidney carcinomas. Various forms of cancer treatment methods have been implemented among the currently approved drugs, including immune modulation therapy, cytokine therapy, mTOR inhibitor, and Vascular Endothelial Growth Factor (VEGF) inhibitor.

Access Research Reports of Kidney Cancer Drugs Market @ https://www.grandviewresearch.com/industry-analysis/kidney-cancer-drugs-market

Further key findings from the report suggest:

Increasing incidence of the disease and rising geriatric population globally are amongst major factors stimulating market growth
Novel agents have expanded market opportunities through larger number of patients under treatment and better treatment prospects compared to traditional therapies. The notable clinical profile of immuno-oncology drugs is reflected their rapid uptake and expansion of indications
The current treatment landscape in metastatic and advanced RCC will shift from TKI and mTOR inhibitors to specific immuno-oncology agents like immune checkpoint inhibitors (ICI), which have demonstrated positive results on PFS as monotherapy (Opdivo) or combination therapy (Opdivo+Yervoy)
U.S. accounted for more than 35.0% of the market in 2016 due to increasing incidence of renal cell carcinoma and presence of key manufacturers in the country. On the other hand, surge in kidney cancer screening is a key driver in markets such as EU
Emerging markets in Asia Pacific and Middle East and Africa are fueled by increasing expenditure on healthcare, a large untapped patient population base due to rise in elderly population, and improvement in diagnostic technologies
Some of the key players operating in this market are Pfizer, Novartis, Bayer, Bristol-Myers Squibb, Eisai, and Exelixis. Collaborations for development, broader product portfolios, and regional expansion in emerging markets are key strategic undertakings of these companies to increase market share.

Grand View Research has segmented the global kidney cancer drugs market based on therapeutic class, pharmacologic class, and country:

Kidney Cancer Drugs Therapeutic Class Outlook (USD Million, 2016 - 2022)

Targeted Therapy
Immunotherapy

Kidney Cancer Drugs Pharmacologic Class Outlook (USD Million, 2016 - 2022)

Angiogenesis Inhibitors
mTOR Inhibitors
Monoclonal Antibodies
Cytokine Immunotherapy (IL-2)

Kidney Cancer Drugs Country Outlook (USD Million, 2016 - 2022)

U.S.
U.K.
France
Germany
Italy
Spain
Japan

Browse Related Category Reports @ https://www.grandviewresearch.com/industry/pharmaceuticals